Mayfair Gold wins Ontario fast-track permitting status for Fenn-Gib as C$310m financing plans advance
Read More Pharma Industry News How does nipocalimab compare to efgartigimod and rozanolixizumab? FcRn class battlelines in gMG and beyond Compare nipocalimab, efgartigimod, and rozanolixizumab on efficacy, safety, dosing, pricing, and market strategy in generalized myasthenia gravis treatment. byPallavi MadhirajuJune 26, 2025